ACLS Provider Course

Incorrect. Asystole is a non-shockable rhythm treated with high-quality CPR and epinephrine.

Incorrect. The 15:2 ratio improves oxygenation and circulation during high-quality infant CPR performed by two rescuers.

Incorrect. Epinephrine is administered every 3-5 minutes during pediatric cardiac arrest to enhance coronary and cerebral perfusion.

Incorrect. Interruptions in chest compressions should not exceed 10 seconds to maintain adequate perfusion to vital organs.

Incorrect. PEA is treated with CPR, epinephrine, and identifying reversible causes to restore organized electrical activity.

Incorrect. High-quality CPR should be resumed immediately after defibrillation to maintain perfusion and increase chances of ROSC.

Incorrect. Asystole is a non-shockable rhythm requiring immediate high-quality CPR and epinephrine to optimize perfusion.

Incorrect. Waveform capnography provides real-time confirmation of ET tube placement and ensures proper ventilation.

Incorrect. Magnesium sulfate stabilizes the cardiac membrane and is the drug of choice for torsades de pointes.

Incorrect. The correct dose of epinephrine for pediatric cardiac arrest is 0.01 mg/kg IV/IO, not 1 mg/kg.

Incorrect. Epinephrine is given to improve perfusion pressure and increase the chance of ROSC in persistent VF.

Incorrect. A sudden increase in PETCO2 is a reliable indicator of ROSC, reflecting improved circulation and gas exchange.

Incorrect. Switching every 2 minutes reduces rescuer fatigue and ensures high-quality chest compressions.

Incorrect. Post-ROSC care focuses on stabilizing ventilation and oxygenation to prevent hypoxia or hyperoxia.

Incorrect. Epinephrine is given as a continuous infusion to maintain adequate heart rate and perfusion when atropine is ineffective.

Incorrect. Biphasic defibrillators deliver effective shocks within the range of 120-200 J to treat VF or pulseless VT.

Incorrect. Atropine is the first-line drug for treating symptomatic bradycardia by increasing heart rate through vagal inhibition.

Incorrect. TTM is used to reduce neurological injury post-ROSC by maintaining a core temperature of 32-36°C.

Incorrect. A rate of 100-120 compressions per minute ensures adequate circulation in pediatric patients.

Incorrect. For unstable narrow, irregular tachycardias, synchronized cardioversion at 120-200 J is recommended.

Incorrect. Hypoxia is one of the most common reversible causes of PEA and is addressed with high-quality oxygenation during resuscitation.

Incorrect. PETCO2 >10 mmHg during CPR indicates effective chest compressions generating sufficient circulation.

Incorrect. A rate of 100-120 compressions per minute optimizes perfusion without compromising cardiac filling.

Incorrect. The correct initial dose of amiodarone for pulseless VT is 300 mg IV/IO, followed by 150 mg for a second dose if needed.

Incorrect. Magnesium sulfate is administered to stabilize the myocardium and treat torsades de pointes effectively.

Incorrect. Naloxone blocks opioid receptors and is administered to reverse opioid overdose and restore adequate respiration.

Incorrect. Delivering 10 breaths per minute ensures adequate oxygenation without causing hyperventilation.

Incorrect. Compressing the chest 2-2.4 inches ensures adequate blood flow while minimizing injury risks.

Incorrect. Two rescuers are needed to maintain high-quality CPR with an advanced airway: one for compressions and one for ventilation.

Incorrect. Rhythm checks are performed every 2 minutes to evaluate for shockable rhythms and assess the effectiveness of interventions.

Incorrect. Amiodarone 300 mg IV/IO is administered after defibrillation and epinephrine to treat refractory VF or pulseless VT.

Incorrect. A compression fraction greater than 80% ensures that most of the resuscitation time is spent performing chest compressions.

Incorrect. CPR is the primary intervention for PEA, followed by epinephrine and identification of reversible causes.

Incorrect. Epinephrine is administered after defibrillation to enhance coronary and cerebral perfusion during resuscitation.

Incorrect. The jaw thrust maneuver opens the airway without moving the cervical spine, reducing the risk of spinal injury.

Incorrect. Synchronized cardioversion at 100 J is effective for restoring a stable rhythm in unstable ventricular tachycardia.

Incorrect. PETCO2 monitoring provides real-time feedback on ventilation and the effectiveness of chest compressions.

Incorrect. Adenosine is used to terminate stable narrow-complex tachycardia by slowing AV node conduction.

Incorrect. Requires immediate defibrillation to restore organized cardiac activity.

Incorrect. Hypovolemia is a reversible cause of cardiac arrest that can be treated with fluid resuscitation to restore circulation.

Incorrect. Magnesium sulfate stabilizes the myocardium and is the first-line treatment for torsades de pointes.

Incorrect. Positioning the patient with a slight left tilt prevents aortocaval compression and improves venous return during CPR.

Incorrect. Maintaining this range prevents hypoxia while minimizing the risks of hyperoxia and oxidative injury.

Incorrect. Magnesium sulfate is used to treat torsades de pointes but is not the first-line drug for VF, where epinephrine is prioritized.

Incorrect. Avoid delays to minimize interruptions in chest compressions and maintain perfusion.

Incorrect. Oxygenation and ventilation should be optimized to avoid hypoxia or hyperoxia during post-cardiac arrest care.

Incorrect. These shockable rhythms require immediate defibrillation to restore a perfusing rhythm.

Incorrect. Asystole is a non-shockable rhythm and is treated with high-quality CPR and epinephrine administration.

Incorrect. Lidocaine is an antiarrhythmic drug used as an alternative to amiodarone for VF or pulseless VT.

Incorrect. Adenosine is the first-line drug for treating narrow-complex SVT by slowing conduction through the AV node.

Incorrect. Pulseless VT is treated with defibrillation, while synchronized cardioversion is reserved for tachyarrhythmias with a pulse.

Incorrect. Atropine at 0.5 mg IV is the first-line treatment for symptomatic bradycardia caused by vagal stimulation.

Incorrect. Pediatric defibrillation begins at 2 J/kg and increases to 4 J/kg for subsequent shocks if needed.

Incorrect. Adenosine is used for narrow-complex SVT, not wide-complex tachycardia, which is typically treated with amiodarone.

Incorrect. PETCO2 monitoring helps assess the effectiveness of both ventilation and chest compressions in real-time during CPR.

Incorrect. Early stabilization of blood pressure and oxygenation is critical to preventing further cardiac arrest after ROSC.

Incorrect. Oxygen saturation should be maintained at 92-96% to prevent hypoxia and avoid the harmful effects of hyperoxia.

Incorrect. Atropine is given at 0.5 mg IV every 3-5 minutes for unstable bradycardia caused by vagal stimulation or primary AV block.

Incorrect. Synchronized cardioversion with 50-100 J is effective for narrow, regular tachycardias that are unstable.

Incorrect. Waveform capnography ensures proper ET tube placement by continuously monitoring exhaled CO? levels.

Incorrect. Pulseless VT is a shockable rhythm requiring immediate defibrillation to restore an organized rhythm.

Incorrect. The jaw thrust maneuver opens the airway without manipulating the cervical spine, protecting against spinal cord injury.

Incorrect. Compressing to one-third the depth of the chest ensures adequate perfusion while minimizing the risk of injury.

Incorrect. Naloxone reverses opioid-induced respiratory depression, restoring normal respiratory function.

Incorrect. Biphasic defibrillation begins at 120-200 J to terminate shockable rhythms like VF and pulseless VT effectively.